Do renal failure and hemodialysis have any effect on the elimination of free and total prostate-specific antigen?

被引:10
作者
Danisman, A [1 ]
Kiliç, S
Kukul, E
Yakupoglu, G
Güntekin, E
Baykara, M
Sevük, M
机构
[1] Akdeniz Univ, Sch Med, Dept Urol, TR-07058 Antalya, Turkey
[2] Akdeniz Univ, Sch Med, Dept Nephrol, TR-07058 Antalya, Turkey
关键词
PSA free; PSA total; renal disease; end-stage; hemodialysis;
D O I
10.1159/000020196
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of this study was first to determine the serum levels of free prostate-specific antigen (f-PSA), total prostate-specific antigen (t-PSA) and f-PSA/t-PSA ratios in patients with renal failure, and secondary, to investigate whether a significant difference between serum f-PSA and t-PSA levels consists in patients with end-stage renal disease before and after hemodialysis, Methods: Serum concentrations of f-PSA and t-PSA were measured in 36 men with end-stage renal disease before and after hemodialysis and in 95 healthy controls. A chemiluminescent enzyme assay was used to determine the levels of f-PSA and t-PSA. Results: The mean concentrations of serum t-PSA were 1.36+/-0.43 ng/ml in patients on hemodialysis and 1.08+/-0.60 ng/ml in controls. There was no significant difference in f-PSA and t-PSA levels between patients with renal failure and controls. F-PSA and t-PSA levels in patients with renal failure also showed no statistical differences before and after hemodialysis. Conclusions: The limited kidney reserve in patients with end-stage renal disease is sufficient to maintain the levels of t-PSA and f-PSA within normal ranges and hemodialysis does not alter the serum levels of different PSA forms. Copyright (C) 2000 S. Karger AG, Basel.
引用
收藏
页码:579 / 581
页数:3
相关论文
共 19 条
[1]   PROSTATE SPECIFIC ANTIGEN DENSITY - A MEANS OF DISTINGUISHING BENIGN PROSTATIC HYPERTROPHY AND PROSTATE-CANCER [J].
BENSON, MC ;
WHANG, IS ;
PANTUCK, A ;
RING, K ;
KAPLAN, SA ;
OLSSON, CA ;
COONER, WH .
JOURNAL OF UROLOGY, 1992, 147 (03) :815-816
[2]   ALPHA(1)-ANTICHYMOTRYPSIN PRODUCTION IN PSA-PRODUCING CELLS IS COMMON IN PROSTATE-CANCER BUT RARE IN BENIGN PROSTATIC HYPERPLASIA [J].
BJORK, T ;
BJARTELL, A ;
ABRAHAMSSON, PA ;
HULKKO, S ;
DISANTAGNESE, A ;
LILJA, H .
UROLOGY, 1994, 43 (04) :427-434
[3]   MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER [J].
CATALONA, WJ ;
SMITH, DS ;
RATLIFF, TL ;
DODDS, KM ;
COPLEN, DE ;
YUAN, JJJ ;
PETROS, JA ;
ANDRIOLE, GL .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) :1156-1161
[4]   COMPARISON OF PROSTATE-SPECIFIC ANTIGEN CONCENTRATION VERSUS PROSTATE-SPECIFIC ANTIGEN DENSITY IN THE EARLY DETECTION OF PROSTATE-CANCER - RECEIVER OPERATING CHARACTERISTIC CURVES [J].
CATALONA, WJ ;
RICHIE, JP ;
DEKERNION, JB ;
AHMANN, FR ;
RATLIFF, TL ;
DALKIN, BL ;
KAVOUSSI, LR ;
MACFARLANE, MT ;
SOUTHWICK, PC .
JOURNAL OF UROLOGY, 1994, 152 (06) :2031-2036
[5]   SERUM PROSTATE-SPECIFIC ANTIGEN COMPLEXED TO ALPHA-1-ANTICHYMOTRYPSIN AS AN INDICATOR OF PROSTATE-CANCER [J].
CHRISTENSSON, A ;
BJORK, T ;
NILSSON, O ;
DAHLEN, U ;
MATIKAINEN, MT ;
COCKETT, ATK ;
ABRAHAMSSON, PA ;
LILJA, H .
JOURNAL OF UROLOGY, 1993, 150 (01) :100-105
[6]   A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER [J].
GANN, PH ;
HENNEKENS, CH ;
STAMPFER, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (04) :289-294
[7]   PROSTATE-SPECIFIC ANTIGEN IS NOT EXCRETED BY HUMAN KIDNEY OR ELIMINATED BY ROUTINE HEMODIALYSIS [J].
KABALIN, JN ;
HORNBERGER, JC .
UROLOGY, 1991, 37 (04) :308-310
[8]   Serum free and total prostate-specific antigen levels in patients with liver disease [J].
Kilic, S ;
Güntekin, E ;
Danisman, A ;
Kukul, E ;
Süleymanlar, I ;
Sevük, M .
UROLOGY, 1998, 52 (05) :825-827
[9]   Determination of the site of metabolism of total, free, and complexed prostate-specific antigen [J].
Kilic, S ;
Yalcinkaya, S ;
Guntekin, E ;
Kukul, E ;
Deger, N ;
Sevuk, M .
UROLOGY, 1998, 52 (03) :470-473
[10]  
LILJA H, 1991, CLIN CHEM, V37, P1618